Compare IOT & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IOT | BBIO |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8B | 15.3B |
| IPO Year | 2021 | 2019 |
| Metric | IOT | BBIO |
|---|---|---|
| Price | $31.68 | $69.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 24 |
| Target Price | $45.42 | ★ $83.00 |
| AVG Volume (30 Days) | ★ 8.3M | 2.8M |
| Earning Date | 06-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.15 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,249,199,000.00 | $502,076,000.00 |
| Revenue This Year | $19.67 | $88.86 |
| Revenue Next Year | $19.62 | $74.11 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 33.26 | ★ 126.26 |
| 52 Week Low | $23.38 | $28.33 |
| 52 Week High | $48.41 | $84.94 |
| Indicator | IOT | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 56.05 | 49.17 |
| Support Level | $23.76 | $61.95 |
| Resistance Level | $36.04 | $79.56 |
| Average True Range (ATR) | 1.59 | 3.33 |
| MACD | 0.57 | 0.53 |
| Stochastic Oscillator | 66.68 | 50.86 |
Samsara Inc provides an end-to-end solution for operations. The company's Connected Operations Platform consolidates data from its IoT devices and a growing ecosystem of connected assets and third-party systems, and makes it easy for organizations to access, analyze, and act on data insights using its cloud dashboard, custom alerts and reports, mobile apps, and workflows.. The company derives almost all of its revenue from subscription services. Geographically, it derives a majority of its revenue from the United States. The company's customers ranges from small and medium-sized businesses to state and local governments.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.